4 years ago

Theolytics Secures Series A Extension for Oncolytic Virus Therapies

  • Theolytics, a UK-based developer of adenovirus product candidates and bioselection systems, has secured an extension to its Series A funding round

  • M Ventures, the strategic venture capital arm of Merck, joined the investor syndicate alongside Epidarex Capital and Taiho Ventures

  • The funding will support the progress of internal programmes in ovarian cancer and a second cancer indication, as well as further advancements in the company's technology platforms

  • Theolytics will also transition to state-of-the-art facilities on Oxford Science Park.

      • ProblemHealthcare

      "Developing effective cancer treatments is a major challenge. Existing therapies often have severe side effects and are not always effective. Oncolytic viruses, which selectively kill cancer cells, offer a promising alternative, but their development is complex and time-consuming."

      Solution

      "Theolytics has developed a large library of potential adenovirus product candidates and breakthrough bioselection systems. These technologies are used to create more effective and targeted oncolytic virus therapies. They are also being applied to develop other adenovirus-based treatments."

      Covered on